| Emily Brooke Zurcher, MD | |
|
1034 N 500 W, Utah Valley Regional Medical Center, Provo, UT 84604-3380 | |
| (801) 357-7850 | |
| (801) 432-2668 |
| Full Name | Emily Brooke Zurcher |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 16 Years |
| Location | 1034 N 500 W, Provo, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336380377 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 9127011-1205 (Utah) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mountain West Anesthesia Llc | 9032018502 | 248 |
News Archive
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
A Center For Global Development "Global Health Policy" blog post reports that the World Bank this week "brought a distinguished group together to discuss new findings, evaluation approaches and policy implications" of conditional cash transfer (CCT) programs, writing "Although 75 percent of published evaluations on CCT programs are sourced from Latin America, newer CCT programs in Burkina Faso, Cambodia, Indonesia, Malawi, Pakistan, Tanzania and Nigeria are beginning to document, analyze and report results."
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.
Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.
› Verified 3 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
A Center For Global Development "Global Health Policy" blog post reports that the World Bank this week "brought a distinguished group together to discuss new findings, evaluation approaches and policy implications" of conditional cash transfer (CCT) programs, writing "Although 75 percent of published evaluations on CCT programs are sourced from Latin America, newer CCT programs in Burkina Faso, Cambodia, Indonesia, Malawi, Pakistan, Tanzania and Nigeria are beginning to document, analyze and report results."
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.
Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.
› Verified 3 days ago
| Entity Name | Mountain West Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558391763 PECOS PAC ID: 9032018502 Enrollment ID: O20040103000057 |
News Archive
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
A Center For Global Development "Global Health Policy" blog post reports that the World Bank this week "brought a distinguished group together to discuss new findings, evaluation approaches and policy implications" of conditional cash transfer (CCT) programs, writing "Although 75 percent of published evaluations on CCT programs are sourced from Latin America, newer CCT programs in Burkina Faso, Cambodia, Indonesia, Malawi, Pakistan, Tanzania and Nigeria are beginning to document, analyze and report results."
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.
Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Brooke Zurcher, MD 150 W Civic Center Dr, Suite 200, Sandy, UT 84070-4230 Ph: (801) 432-2600 | Emily Brooke Zurcher, MD 1034 N 500 W, Utah Valley Regional Medical Center, Provo, UT 84604-3380 Ph: (801) 357-7850 |
News Archive
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
A Center For Global Development "Global Health Policy" blog post reports that the World Bank this week "brought a distinguished group together to discuss new findings, evaluation approaches and policy implications" of conditional cash transfer (CCT) programs, writing "Although 75 percent of published evaluations on CCT programs are sourced from Latin America, newer CCT programs in Burkina Faso, Cambodia, Indonesia, Malawi, Pakistan, Tanzania and Nigeria are beginning to document, analyze and report results."
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.
Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.
› Verified 3 days ago
Dr. Daniel Rey Faber, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 280 River Park Dr, #200, Provo, UT 84604 Phone: 801-223-4860 Fax: 801-371-8993 | |
John B Zimmerman, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 | |
David Groesbeck, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 | |
Carl Thayne Wilson, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 | |
Mr. Matthew David Wagaman, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-7850 Fax: 770-701-6675 | |
Mitchell D Albrecht, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84004 Phone: 801-993-9582 Fax: 801-733-5618 | |
Mark Critchfield, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 |